Veritable’s Bristol-Myers Squibb BMY Stock Holding History

Veritable’s Portfolio BMY Stock Details BMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-129,154	Closed	-$8.26M	–	98
2023 Q2	$8.26M	Buy	129,154 +49,997	+63%	+$3.35M	0.13%	87
2023 Q1	$5.49M	Buy	79,157 +5,974	+8%	+$421K	0.09%	114
2022 Q4	$5.27M	Buy	73,183 +1,499	+2%	+$113K	0.09%	112
2022 Q3	$5.1M	Sell	71,684 -43,363	-38%	-$3.15M	0.1%	107
2022 Q2	$8.86M	Buy	115,047 +7,191	+7%	+$548K	0.16%	75
2022 Q1	$7.88M	Buy	107,856 +1,045	+1%	+$70.2K	0.12%	90
2021 Q4	$6.66M	Buy	106,811 +650	+0.6%	+$38.1K	0.1%	110
2021 Q3	$6.28M	Sell	106,161 -489	-0.5%	-$32.2K	0.1%	109
2021 Q2	$7.13M	Buy	106,650 +1,087	+1%	+$70.9K	0.11%	90
2021 Q1	$6.66M	Sell	105,563 -30,726	-23%	-$1.91M	0.11%	95
2020 Q4	$8.45M	Sell	136,289 -115,288	-46%	-$7.09M	0.16%	79
2020 Q3	$15.2M	Buy	251,577 +898	+0.4%	+$54K	0.3%	42
2020 Q2	$14.7M	Sell	250,679 -9,476	-4%	-$567K	0.32%	38
2020 Q1	$14.5M	Buy	260,155 +47,395	+22%	+$2.9M	0.35%	37
2019 Q4	$13.7M	Buy	212,760 +37,383	+21%	+$2.14M	0.25%	55
2019 Q3	$8.89M	Buy	175,377 +2,924	+2%	+$137K	0.17%	82
2019 Q2	$7.82M	Sell	172,453 -1,331	-0.8%	-$62K	0.16%	89
2019 Q1	$8.29M	Buy	173,784 +906	+0.5%	+$45.1K	0.17%	89
2018 Q4	$8.99M	Sell	172,878 -55,743	-24%	-$2.99M	0.2%	75
2018 Q3	$14.2M	Buy	228,621 +2,986	+1%	+$177K	0.29%	44
2018 Q2	$12.5M	Sell	225,635 -3,573	-2%	-$193K	0.26%	52
2018 Q1	$14.5M	Sell	229,208 -3,630	-2%	-$234K	0.31%	38
2017 Q4	$14.3M	Sell	232,838 -28,130	-11%	-$1.76M	0.29%	44
2017 Q3	$16.6M	Sell	260,968 -1,930	-0.7%	-$113K	0.35%	32
2017 Q2	$14.6M	Sell	262,898 -345	-0.1%	-$18.8K	0.33%	40
2017 Q1	$14.3M	Buy	263,243 +5,079	+2%	+$279K	0.34%	36
2016 Q4	$15.1M	Buy	258,164 +765	+0.3%	+$41.8K	0.37%	35
2016 Q3	$13.9M	Sell	257,399 -6,667	-3%	-$428K	0.35%	36
2016 Q2	$19.4M	Sell	264,066 -3,406	-1%	-$241K	0.49%	26
2016 Q1	$17.1M	Buy	267,472 +9,489	+4%	+$598K	0.45%	28
2015 Q4	$17.7M	Buy	257,983 +50,913	+25%	+$3.36M	0.49%	27
2015 Q3	$12.3M	Buy	207,070 +1,795	+0.9%	+$114K	0.36%	37
2015 Q2	$13.7M	Sell	205,275 -88,971	-30%	-$5.86M	0.37%	35
2015 Q1	$19M	Buy	294,246 +3,165	+1%	+$198K	0.4%	39
2014 Q4	$17.2M	Sell	291,081 -3,491	-1%	-$197K	0.36%	41
2014 Q3	$15.1M	Buy	294,572 +23,106	+9%	+$1.15M	0.32%	51
2014 Q2	$13.2M	Buy	271,466 +633	+0.2%	+$31.2K	0.28%	56
2014 Q1	$14.1M	Sell	270,833 -4,294	-2%	-$228K	0.31%	57
2013 Q4	$14.6M	Sell	275,127 -10,622	-4%	-$541K	0.32%	51
2013 Q3	$13.2M	Buy	285,749 +425	+0.1%	+$18.7K	0.31%	55
2013 Q2	$12.8M	Buy	+285,324	New	+$12.4M	0.31%	55

Other funds holding BMY

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Veritable's BMY Position: Q3 2023 in Review

Veritable sold out of Bristol-Myers Squibb (BMY) in Q3 2023, closing a stake of 129,154 shares — an estimated $8.26M sold.

Veritable first reported a position in BMY in Q2 2013 and held it in 41 quarters. The position peaked at $19.4M in Q2 2016. 2,387 funds tracked by Wall St. Rank hold BMY as of Q3 2023.

Veritable reported no remaining Bristol-Myers Squibb position as of Q3 2023 after selling out during the quarter.
Veritable sold 129,154 Bristol-Myers Squibb shares in Q3 2023, an estimated $8.26M.
Veritable first reported a position in Bristol-Myers Squibb in Q2 2013 and held it in 41 quarters.
Veritable's Bristol-Myers Squibb position peaked at $19.4M in Q2 2016.
2,387 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q3 2023.

Based on Veritable's 13F filing for Q3 2023.